Skip to content

post

Chemo Radiation For Distant Mets Ups Survival in Anal Cancer

    Emerging data indicate that aggressive treatment of distant metastasis can improve survival in some types of advanced anal cancer, say researchers. Results from a retrospective review of 30 patients with stage IV anal cancer who had distant metastasis limited to the para-aortic (PA) lymph nodes show that a combination of extended-field radiation therapy and chemotherapy… Read More »Chemo Radiation For Distant Mets Ups Survival in Anal Cancer

    US Survey : 39% Say Alternative Therapies Can Cure Cancer

      Nearly 4 in 10 Americans (39%) “somewhat” or “strongly” agree that cancer can be cured solely through “alternative” therapies, such as oxygen therapy, diet, and herbs, without standard cancer treatments, according to a national survey commissioned by the American Society of Clinical Oncology (ASCO). The survey, which probed public opinion about a variety of cancer-related… Read More »US Survey : 39% Say Alternative Therapies Can Cure Cancer

      Outstanding Ovarian Cancer PFS With Olaparib Maintenance.

        A first-of-its kind phase 3 study found that patients with advanced ovarian cancer who carry a BRCA mutation have a marked increase in progression-free survival (PFS) if they are given maintenance therapy with the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib (Lynparza, AstraZeneca) following successful first-line chemotherapy. Kathleen Moore, MD The finding comes from the SOLO1 study,… Read More »Outstanding Ovarian Cancer PFS With Olaparib Maintenance.

        FDA OKs Durvalumab( Imfinz)For Reducing Risk For NSCLC Progression.

          The US Food and Drug Administration (FDA) today approved durvalumab (Imfinzi, AstraZeneca) for the treatment of patients with stage III non–small cell lung cancer (NSCLC) whose tumors are unresectable and whose cancer has not progressed after chemoradiation. The immunotherapy becomes the first treatment approved to reduce the risk of the cancer progressing in this setting.… Read More »FDA OKs Durvalumab( Imfinz)For Reducing Risk For NSCLC Progression.

          RT Plus Chemo Triples PFS In Limited Metastatic Lung Cancer.

            Consolidation treatment with stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy almost tripled progression-free survival (PFS) in patients with limited metastatic non–small cell lung cancer (NSCLC) compared to maintenance chemotherapy alone. A new analysis showed that there was a statistically significant improvement in PFS from 3.5 to 9.7 months with the addition of consolidative radiotherapy… Read More »RT Plus Chemo Triples PFS In Limited Metastatic Lung Cancer.

            Payment method: Bank Transfer

              Regarding bank transfer, GDMeds, now, offer one more option – check local bank account first. To date, GDMeds has opened several bank accounts in different countries around the world. For the customer who chooses this option, GDMeds will offer the local bank account for the payment transfer if have. Compared with the international bank transfer,… Read More »Payment method: Bank Transfer

              Compare Harvoni vs. Epclusa

                Harvoni (ledipasvir / sofosbuvir) Myhep Lvir, Hepcinat, Ledihep, etc Epclusa (velpatasvir / sofosbuvir) Mylan All, Velpanat, Sovihep, Resof, etc. Treats hepatitis C. Harvoni (ledipasvir / sofosbuvir) is a combination pill for hepatitis C that you only need to take once a day. Depending on the amount of liver damage you have, it’s sometimes taken together… Read More »Compare Harvoni vs. Epclusa

                Did They Die Of Prostrate Cancer

                  An audit of death certificates from Norway has found that one third of all deaths attributed to prostate cancer were actually caused by something else. However, there was also an underreporting of prostate deaths in the study — wherein some men who were reported to have died of other causes were considered by the researchers… Read More »Did They Die Of Prostrate Cancer

                  Four Treatment For Mastectomy Pain,But ‘No Magic Drug’.

                    Postmastectomy pain syndrome is a “major clinical challenge,” but four treatment modalities have been found to have a “significant effect” on the pain, conclude the authors of a new review systematic review of the subject. However, another expert laid emphasis elsewhere, saying there is “no magic drug” and that some patients feel their ongoing, intractable… Read More »Four Treatment For Mastectomy Pain,But ‘No Magic Drug’.